TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07284459: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Sponsor: Contineum Therapeutics · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 324 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT07284459 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07284459 Rescue Dossier →